A Phase I Study of JSKN021 in Advanced Solid Tumors

Summary

This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.

Timeline

Start

2026-05-31

Primary completion

2028-10-31

Completion

2029-05-31

Drugs

Indications